A University of Colorado research team will be studying the O2matic’s proprietary oxygen therapy technology via a project funded by the U.S. Department of Defense.
In a May 21 announcement, O2matic, based in Denmark, said the research project will be led by Adit Ginde, M.D., professor of emergency medicine and anesthesiology at the University of Colorado’s School of Medicine.
“Dr. Ginde and his team’s work has paved the way for the SAVE-O2 trial, a multi-center randomized clinical trial funded by the U.S. Department of Defense,” the announcement said. “The SAVE-O2 trial focuses on redefining oxygen requirements in critically ill trauma patients through targeting normoxemia.
“Preliminary results from analyzing data from approximately 12,000 randomized patients have unveiled promising outcomes. Manually targeting normoxemia successfully reduces hyperoxemia without increasing hypoxemia, resulting in lower mortality rates, shortened hospital stays, and decreased supplemental oxygen requirements.”
Ginde presented his team’s initial research results at the 2023 Military Health System Research Symposium. The presentation earned the team an Outstanding Research Accomplishment award.
The team is “now evaluating the efficacy of automatic oxygen therapy technology, with O2matic’s proprietary technology chosen for a multi-center study involving 300 patients,” the news announcement added. “This study, named SAVE-O2 AI, and initiated in May 2024, aims to publish results by early 2026.
Funding support from the Department of Defense came through the Medical Technology Enterprise Consortium, which furthers “oxygen research using autonomous solutions.”
O2matic’s technology monitors a patient’s oxygen saturation and automatically adjusts oxygen dosage as needed, thus eliminating the need for dosages to be manually adjusted.
O2matic’s PRO 100 system “modernizes traditional manual oxygen titration by continuously measuring the patient’s blood oxygen level & pulse utilizing a sensor (pulse oximeter) and automatically adjusting the oxygen dose based on the data through advanced algorithms,” the company said. “In case the patient’s condition should require the attention, the device will notify the medical staff using its alarm system. Furthermore, O2matic can automate the phasing out of oxygen therapy.”
O2matic also offers a Home Oxygen Therapy system — the HOT 100 — for oxygen patients living at home. The system measures the patient’s oxygen needs two to three times a day and adjusts oxygen as needed. “HOT 100 monitors and titrates oxygen based on the patient’s condition and optimizes oxygen treatment by regulating the oxygen supply based on a frequent measurement of the blood oxygen content,” O2matic said.
“We at O2matic are deeply honored to be part of this significant study and eagerly anticipate the potential impact of our technology on acute and trauma patients,” said Arnt Lund, CEO of O2matic. “We are also grateful to the IDE sponsor for this study, IDTS Medical Inc., and its CEO, Mario Nozzarella, who guided us through the U.S. Food and Drug Administration Investigational Device Exemption (US FDA IDE) process and received our final (non-conditional) letter regarding the submission G230325/A001 with a strong sense of urgency.”
